Moscow, Feb 28 (Prensa Latina) Russia and Cuba are betting on developing the biotechnology and pharmaceutical industries, so much so that they are working to create the first joint venture in the biopharmaceutical sector by 2025.
“In recent years we have found fertile ground for collaboration between our countries. As a result of these ties, it is expected that during this year the first joint venture in the Cuban biopharmaceutical industry will emerge, an ambassador for our products in Russia,” BioCubaFarma First Vice President Eulogio Pimentel told Prensa Latina exclusively.
After concluding a meeting with around twenty representatives of companies dedicated to the production, distribution and marketing of medicines and medical supplies from the Eurasian giant, where the Caribbean nation presented the potential of the sector, the Cuban executive commented on some of the main Cuban drugs currently used in the treatment of Russian patients.
The executive of the business group in charge of producing, innovating, marketing and delivering the renowned medicines to the world commented that as a result of exports in the territory of the Slavic nation, products such as Heberprot-P and Hebermin are already available, and they are working on the sanitary registration of Nimotuzumab, a monoclonal antibody against various oncological diseases.
“We are also in the process of registering the VA-Mengoc-BC vaccine against meningococcal meningitis of serogroup BC, and we are also in the stage of completing clinical development in Russia of the therapeutic vaccine against lung cancer CIMAvax and Jusvinza, a drug for treating autoimmune diseases such as rheumatoid arthritis, as well as other projects in the oncology field,” he stressed.
Pimentel compared the actions carried out between Moscow and Havana as a two-way highway, through which Cuban technologies are transferred for the benefit of the population of the Russian Federation, and at the same time they seek to register Russian medicines to benefit the Cuban people.
The Slavic nation’s counterparts expressed their interest in the Cuban market, especially the general director of the Chemrar Pharmaceutical Group, Denis Vinokurov, who highlighted the positive increase in collaboration, not only in import and export, but also in the scientific field and in the development of original products in each country with the consent of their specialists.
Likewise, the Director General of the National Committee for Economic Cooperation with Latin American Countries, Tatiana Mashkova, highlighted the importance of strengthening ties in the sector, as “Cuba is an international powerhouse in the innovation of treatments for the most important diseases for humanity,” she emphasized.
The delegation from the Caribbean nation that is currently visiting Russia, and previously visited Belarus, also includes the director of the Medicuba company, Armando Garrido, and Olga Lidia Jacobo, director of the Center for State Control of Medicines, Equipment and Medical Devices of Cuba.
Both representatives outlined the potential of their institutions, their interest in entering the Russian market with greater emphasis, and the mutually beneficial actions that can continue to be deployed in favor of both peoples.
Finally, BioCubaFarma executives invited their Russian colleagues to participate in the next edition of the Cuba 2025 Health Fair, scheduled to be held in Havana from April 21 to 25.
arc/odf
